Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future ...
Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology ...
Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...
A patient with acute myeloid leukemia received a bone marrow transplant from a deceased donor, achieved engraftment, and has ...
Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia, or ...
particularly by inhibiting a specific cancer-driving protein within the complex—BPTF—could provide a new approach to treating ...
In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...
Despite the promising data, Syndax Pharmaceuticals saw its stock plummet by -21.49% in premarket trading after the latest update on its AUGMENT-101 trial. As of Tuesday morning, the stock was trading ...
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
Oct. 9, 2024 — Researchers have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions. The technology accurately ...
1d
Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback